Glucose Kabipac

Glucose Kabipac is a prescription‑only intravenous solution that contains glucose monohydrate as its sole active ingredient. The product is supplied as a sterile solution for injection, with the exact concentration not publicly disclosed. Designed for use in the European market, Glucose Kabipac delivers a readily absorbable carbohydrate directly into the bloodstream, supporting energy provision and fluid balance in clinical settings and electrolyte homeostasis during treatment.

Glucose Kabipac is indicated for several clinical situations where rapid carbohydrate supplementation or fluid replacement is required.

- Management of acute hypoglycemia in patients who cannot take oral glucose, providing a rapid rise in plasma glucose. - Inclusion in total parenteral nutrition (TPN) solutions to supply carbohydrate calories for patients with non‑functional gastrointestinal tracts. - Provision of isotonic fluid and electrolyte balance during surgery, trauma resuscitation, or severe dehydration. - Maintenance of adequate blood glucose concentrations in critically ill or fasting individuals receiving intensive care. - Use as a compatible diluent for intravenous medications that require a carbohydrate‑based carrier.

When administered intravenously, Glucose Kabipac may be associated with a range of adverse reactions, most of which are related to its osmotic and metabolic properties.

Common: - Transient hyperglycemia or elevated blood glucose levels. - Local irritation or pain at the injection site. - Mild electrolyte shifts, such as decreased serum potassium. - Nausea or mild gastrointestinal discomfort.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload or pulmonary edema in patients with compromised cardiac function. - Hypersensitivity reactions, including rash, urticaria, or anaphylaxis. - Metabolic acidosis in the setting of large-volume administration.

Clinicians should observe specific precautions when prescribing Glucose Kabipac to minimize risks and ensure safe use.

- Assess baseline blood glucose and adjust infusion rate in diabetic or hyperglycemic patients. - Monitor fluid balance and cardiac status to avoid overload, especially in heart failure or renal impairment. - Check serum electrolytes before and during therapy, correcting abnormalities as needed. - Use aseptic technique and inspect the solution for particulate matter or discoloration before administration. - Avoid rapid infusion rates that exceed recommended guidelines for osmolarity. - Consider pregnancy and lactation status; limited data are available, so use only if clearly indicated.

Glucose Kabipac can interact with other medications or clinical conditions, influencing its safety or efficacy.

Avoid: - Co‑administration with insulin or other rapid‑acting glucose‑lowering agents without appropriate dose adjustments. - Simultaneous infusion of high‑osmolarity solutions that may increase the risk of phlebitis.

Use with caution: - Concurrent use of diuretics that may exacerbate electrolyte disturbances. - Administration alongside catecholamines or glucocorticoids, which can affect glucose metabolism. - Patients receiving total parenteral nutrition containing other carbohydrate sources; monitor total caloric load.